Switch theme
Sign up to access all valuation multiples
Jiangsu Yuyue Medical Equipment And Supply Co Ltd is engaged in providing household medical devices, medical clinical products, and related medical services, R&D, manufacturing and sales of medical device products, and providing related solutions. The company's products are mainly focused on respiratory oxygen production, diabetes care, infection control solutions, household electronic testing and in vitro diagnostics, first aid, and clinical and rehabilitation devices.
2007
6.1K+
LTM Revenue $1.1B
LTM EBITDA $274M
$4.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Yuyue Medical has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $274M.
In the most recent fiscal year, Jiangsu Yuyue Medical achieved revenue of $1.1B and an EBITDA of $306M.
Jiangsu Yuyue Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Yuyue Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $558M | XXX | $527M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $274M | XXX | $306M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $283M | XXX | $241M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $265M | XXX | $251M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiangsu Yuyue Medical's stock price is CNY 38 (or $5).
Jiangsu Yuyue Medical has current market cap of CNY 37.9B (or $5.3B), and EV of CNY 30.8B (or $4.3B).
See Jiangsu Yuyue Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.3B | $5.3B | XXX | XXX | XXX | XXX | $0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiangsu Yuyue Medical has market cap of $5.3B and EV of $4.3B.
Jiangsu Yuyue Medical's trades at 4.1x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Jiangsu Yuyue Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Yuyue Medical has a P/E ratio of 19.9x.
See valuation multiples for Jiangsu Yuyue Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.3B | XXX | $5.3B | XXX | XXX | XXX |
| EV (current) | $4.3B | XXX | $4.3B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | 15.6x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 15.1x | XXX | 17.8x | XXX | XXX | XXX |
| EV/Gross Profit | 7.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 18.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangsu Yuyue Medical's last 12 month revenue growth is 13%
Jiangsu Yuyue Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $47K for the same period.
Jiangsu Yuyue Medical's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Yuyue Medical's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangsu Yuyue Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | -17% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $47K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Yuyue Medical acquired XXX companies to date.
Last acquisition by Jiangsu Yuyue Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Yuyue Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiangsu Yuyue Medical founded? | Jiangsu Yuyue Medical was founded in 2007. |
| Where is Jiangsu Yuyue Medical headquartered? | Jiangsu Yuyue Medical is headquartered in China. |
| How many employees does Jiangsu Yuyue Medical have? | As of today, Jiangsu Yuyue Medical has 6.1K+ employees. |
| Is Jiangsu Yuyue Medical publicy listed? | Yes, Jiangsu Yuyue Medical is a public company listed on SHE. |
| What is the stock symbol of Jiangsu Yuyue Medical? | Jiangsu Yuyue Medical trades under 002223 ticker. |
| When did Jiangsu Yuyue Medical go public? | Jiangsu Yuyue Medical went public in 2008. |
| Who are competitors of Jiangsu Yuyue Medical? | Similar companies to Jiangsu Yuyue Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Jiangsu Yuyue Medical? | Jiangsu Yuyue Medical's current market cap is $5.3B |
| What is the current revenue of Jiangsu Yuyue Medical? | Jiangsu Yuyue Medical's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Jiangsu Yuyue Medical? | Jiangsu Yuyue Medical revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Jiangsu Yuyue Medical? | Current revenue multiple of Jiangsu Yuyue Medical is 3.9x. |
| Is Jiangsu Yuyue Medical profitable? | Yes, Jiangsu Yuyue Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangsu Yuyue Medical? | Jiangsu Yuyue Medical's last 12 months EBITDA is $274M. |
| What is Jiangsu Yuyue Medical's EBITDA margin? | Jiangsu Yuyue Medical's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Jiangsu Yuyue Medical? | Current EBITDA multiple of Jiangsu Yuyue Medical is 15.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
